Deletion of the mammalian INDY homolog mimics aspects of dietary restriction and protects against adiposity and insulin resistance in mice.

Howard Hughes Medical Institute, Yale School of Medicine, New Haven, CT 06520, USA.
Cell metabolism (Impact Factor: 17.35). 08/2011; 14(2):184-95. DOI: 10.1016/j.cmet.2011.06.009
Source: PubMed

ABSTRACT Reduced expression of the Indy (I'm Not Dead, Yet) gene in D. melanogaster and its homolog in C. elegans prolongs life span and in D. melanogaster augments mitochondrial biogenesis in a manner akin to caloric restriction. However, the cellular mechanism by which Indy does this is unknown. Here, we report on the knockout mouse model of the mammalian Indy (mIndy) homolog, SLC13A5. Deletion of mIndy in mice (mINDY(-/-) mice) reduces hepatocellular ATP/ADP ratio, activates hepatic AMPK, induces PGC-1α, inhibits ACC-2, and reduces SREBP-1c levels. This signaling network promotes hepatic mitochondrial biogenesis, lipid oxidation, and energy expenditure and attenuates hepatic de novo lipogenesis. Together, these traits protect mINDY(-/-) mice from the adiposity and insulin resistance that evolve with high-fat feeding and aging. Our studies demonstrate a profound effect of mIndy on mammalian energy metabolism and suggest that mINDY might be a therapeutic target for the treatment of obesity and type 2 diabetes.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Epileptic encephalopathy (EE) refers to a clinically and genetically heterogeneous group of severe disorders characterized by seizures, abnormal interictal electro-encephalogram, psychomotor delay, and/or cognitive deterioration. We ascertained two multiplex families (including one consanguineous family) consistent with an autosomal-recessive inheritance pattern of EE. All seven affected individuals developed subclinical seizures as early as the first day of life, severe epileptic disease, and profound developmental delay with no facial dysmorphism. Given the similarity in clinical presentation in the two families, we hypothesized that the observed phenotype was due to mutations in the same gene, and we performed exome sequencing in three affected individuals. Analysis of rare variants in genes consistent with an autosomal-recessive mode of inheritance led to identification of mutations in SLC13A5, which encodes the cytoplasmic sodium-dependent citrate carrier, notably expressed in neurons. Disease association was confirmed by cosegregation analysis in additional family members. Screening of 68 additional unrelated individuals with early-onset epileptic encephalopathy for SLC13A5 mutations led to identification of one additional subject with compound heterozygous mutations of SLC13A5 and a similar clinical presentation as the index subjects. Mutations affected key residues for sodium binding, which is critical for citrate transport. These findings underline the value of careful clinical characterization for genetic investigations in highly heterogeneous conditions such as EE and further highlight the role of citrate metabolism in epilepsy.
    The American Journal of Human Genetics 07/2014; 95(1):113-20. DOI:10.1016/j.ajhg.2014.06.006 · 10.99 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The solute carrier family 13 member 5 (SLC13A5) is a sodium-coupled transporter that mediates cellular uptake of citrate, which plays important roles in the synthesis of fatty acids and cholesterol. Recently, the pregnane X receptor (PXR, NR1I2) initially characterized as a xenobiotic sensor, has been functionally linked to the regulation of various physiological processes that are associated with lipid metabolism and energy homeostasis. Here, we show that the SLC13A5 gene is a novel transcriptional target of PXR and altered expression of SLC13A5 affects lipid accumulation in human liver cells. The prototypical PXR activator rifampicin markedly induced the mRNA and protein expression of SLC13A5 in human primary hepatocytes. Utilizing cell-based luciferase reporter assays, electrophoretic mobility shift assays, and chromatin immunoprecipitation assays, we identified and functionally characterized two enhancer modules located upstream of the SLC13A5 gene transcription start site, that are associated with regulation of PXR-mediated SLC13A5 induction. Functional analysis further revealed that rifampicin can enhance lipid accumulation in human primary hepatocytes; and knockdown of SLC13A5 expression alone leads to significant decrease of the lipid content in HepG2 cells. Overall, our results uncover SLC13A5 as a novel target gene of PXR and may contribute to drug-induced steatosis and metabolic disorders in humans. The American Society for Pharmacology and Experimental Therapeutics.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apolipoprotein A5 (ApoA5) has a critical role in the regulation of plasma triglyceride (TAG) concentrations. In order to determine if ApoA5 also impacts ectopic lipid deposition in liver and skeletal muscle as well as insulin sensitivity we treated mice with an antisense oligonucleotide (ASO) to decrease hepatic expression of ApoA5. ASO treatment reduced ApoA5 protein expression in liver by 60-70%. ApoA5 ASO-treated mice displayed approximately 3-fold higher plasma TAG concentrations, which was associated with decreased plasma TAG clearance. Furthermore, ApoA5 knockdown mice fed a high-fat diet (HFD) exhibited reduced liver and skeletal muscle TAG uptake and reduced liver and muscle TAG and diacylglycerol (DAG) content. HFD ASO-treated mice manifested protection from HFD-induced insulin resistance assessed by a hyperinsulinemic-euglycemic clamp, which could be attributed to increases in both hepatic and peripheral insulin responsiveness. This protection from lipid-induced liver and muscle insulin resistance could be attributed to decreased DAG activation of PKCε and PKCθ in liver and muscle respectively and increased insulin-stimulated AKT2 phosphorylation in these tissues. In summary, these studies demonstrate a novel gene-environment interaction for ApoA5 in the regulation of ectopic lipid accumulation in liver and skeletal muscle and the susceptibility to diet-induced liver and muscle insulin resistance. Copyright © 2014, The American Society for Biochemistry and Molecular Biology.
    The Journal of Lipid Research 12/2014; DOI:10.1194/jlr.M054080 · 4.73 Impact Factor

Full-text (2 Sources)

Available from
May 31, 2014